Jump to navigation

Navigation
  • Sign in

Search form

Top Menu

  • Newsletters
  • Español
Home
  • Español
  • About the Study
  • Virtual TownHall
  • FAQ
  • For Providers
  • For Participants
Find your study site

California

  • UCLA CARE Center and Clinic
  • UCSF Mt. Zion Medical Center

Colorado

  • Denver Public Health
  • University of Colorado Denver

DC

  • Dupont Circle Physicians Group
  • Washington DC - Capital Digestive Care

Florida

  • University of Miami Health System

Georgia

  • Emory University - Grady Hospital

Illinois

  • Anal Dysplasia Clinic Midwest

Massachusetts

  • Boston Medical Center

New Jersey

  • NJMS Clinical Research Unit

New York

  • Cornell Clinical Trials Unit
  • Laser Surgery Care
  • Montefiore Medical Center

North Carolina

  • Wake Forest Baptist Medical Center

Puerto Rico

  • University of Puerto Rico

Washington

  • Harborview Medical Center
  • Virginia Mason Medical Center

Don't see your state?

  • Find out why
  • About the Study
    • A reality check (and resources!) on all things anal cancer
    • Featured & Fact 1
    • National Team
    • Spread the Word
    • The CAB
  • Virtual TownHall
  • FAQ
    • Anal Cancer Basics
    • Anal Cancer Risk Compared
    • How is HSIL Treated?
    • Que es IRC?
    • What is HPV?
  • For Providers
    • Why Anchor?
    • What to Tell Patients
    • Evidence & Data
    • Accountability
  • For Participants
    • Need a Reminder?
    • Let's Talk
    • Newsletter

Search form

  • Newsletters
  • The ANCHOR Study
  • Community Advisory Board
  • Meet the National Team
  • Anal Cancer Risk Compared
  • Spread the Word
  • Study News
  • Frequently Asked Questions"
  • What is HPV?
  • Anal Cancer Basics
  • How is HSIL Treated?
  • How Do I Sign Up?
  • What Risks Are Involved?
  • What is IRC?
  • Atlanta - Emory
  • Boston Medical Center
  • Chicago - Midwest
  • Denver - Public Health
  • Denver - U. Colorado Denver
  • DC - Capital Digestive Care
  • DC - Dupont Circle
  • LA - UCLA Care Center
  • LA - UCLA School of Nursing
  • Miami
  • NOLA - Crescent Care
  • NOLA - LSU
  • NY - Cornell
  • NY - Laser Surgery Care
  • NY - Montefiore
  • Puerto Rico
  • San Francisco
  • Seattle - Harborview
  • Seattle - Polyclinic
  • Seattle - Virginia Mason
  • Winston-Salem
  • For Our Participants
  • Need a Reminder?
  • Let's Talk
  • Newsletter
  • For Providers
  • Why Anchor?
  • What to Tell Patients
  • Evidence & Data
  • Accountability

ANCHOR Study Showed that Treatment Can Prevent Anal Cancer!

Treating anal cancer precursor lesions reduces cancer risk for people living with HIV. The Study’s results have been published in peer-reviewed publications and are being shared now because of the public health importance of the findings.

Read the press release How does this affect participants?

We are still following participants through September 2024

Please continue to come in for study visits. By participating, you can continue to help advance this research and improve people’s lives, in addition to taking care of your own health. Now that we know that treatment can help prevent anal cancer, we strongly recommend that everyone get treatment. We are still collecting data to answer questions about who needs HRA and treatment, and which anal HSIL lesions are more likely to progress to cancer. Study follow-up will continue until September 30, 2024

More Information

FAQs

View our frequently asked questions.

Learn More

Latest News in the Study: 

Listen: An Intersectional Look at Anal Cancer and HIV

07/28/22

Listen to an indepth conversation between the ANCHOR Study's Protocol Chair and Professor of Medicine at UCSF, Dr. Joel Palefsky, and the Director

Listen: Anal Cancer - It’s Time to Get Our Butts in Gear!

07/28/22

Hear a key conversation between ANCHOR Study investigator, Dr. Jessica Korman, and The BodyPro's, Miles Helfand, about how the ANCHOR Study is

NEJM: Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer

06/16/22

The incidence of anal cancer is substantially higher among persons living with the human immunodeficiency virus (HIV) than in the general

View All

Learn More About This National Study

Frequently Asked Questions
Information on Anal Cancer
Meet the Researchers
Why This Study is Historic

"ANCHOR data show for the first time that, like cervical cancer, anal cancer can be prevented even in high-risk populations, such as people living with HIV, who often have HSIL that can be difficult to treat."

- Dr. Joel Palefsky, Principal Investigator
Contact the National Study Investigators
844-448-2888
AMC
This study is funded by a grant from the
National Cancer Institute of the National Institutes of Health
under an award to the AIDS Malignancy Consortium.

Help Spread the Word

Privacy PolicyTerms of Use
© 2021 The Anchor Study